DOCSLIB.ORG

Therapeutic Class Brand Name P a Status Generic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Class Brand Name P a Status Generic P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 40MG CAPSULE Acne Agents, Systemic SOTRET ISOTRETINOIN 30MG CAPSULE Acne Agents, Topical BENZACLIN CLINDAMYCIN PHOSPHATE/BEN 1-5% GEL Acne Agents, Topical KLARON SULFACETAMIDE SODIUM 10% LOTION Adrenal Steroid Inhibitors CYTADREN AMINOGLUTETHIMIDE 250MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 10MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 12.5MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 15MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 20MG TABLET P A Therapeutic Class Brand Name Status Generic Name Strength Form Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 30MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 5MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL AMPHET ASP/AMPHET/D-AMPHE 7.5MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL XR AMPHET ASP/AMPHET/D-AMPHE 10MG CAP.SR 24H Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL XR AMPHET ASP/AMPHET/D-AMPHE 15MG CAP.SR 24H Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL XR AMPHET ASP/AMPHET/D-AMPHE 20MG CAP.SR 24H Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL XR AMPHET ASP/AMPHET/D-AMPHE 25MG CAP.SR 24H Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL XR AMPHET ASP/AMPHET/D-AMPHE 30MG CAP.SR 24H Adrenergic Agents, Aromatic, Non- Catecholamine ADDERALL XR AMPHET ASP/AMPHET/D-AMPHE 5MG CAP.SR 24H Adrenergic Agents, Aromatic, Non- Catecholamine DESOXYN METHAMPHETAMINE HCL 5MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine DEXEDRINE D-AMPHETAMINE SULFATE 10MG CAPSULE SA P A Therapeutic Class Brand Name Status Generic Name Strength Form Adrenergic Agents, Aromatic, Non- Catecholamine DEXEDRINE D-AMPHETAMINE SULFATE 15MG CAPSULE SA Adrenergic Agents, Aromatic, Non- Catecholamine DEXEDRINE D-AMPHETAMINE SULFATE 5MG CAPSULE SA Adrenergic Agents, Aromatic, Non- Catecholamine DEXEDRINE D-AMPHETAMINE SULFATE 5MG TABLET Adrenergic Agents, Aromatic, Non- Catecholamine DEXEDRINE D-AMPHETAMINE SULFATE 5MG/5ML ELIXIR Adrenergic Agents, Aromatic, Non- Catecholamine DEXTROSTAT D-AMPHETAMINE SULFATE 10MG TABLET Adrenergic Agents, Catecholamines ADRENALIN CHLORIDE EPINEPHRINE 1MG/ML VIAL Adrenergic Agents, Catecholamines EPINEPHRINE EPINEPHRINE 1MG/ML AMPUL Adrenergic Agents, Catecholamines ISOETHARINE HCL ISOETHARINE HCL 10MG/ML SOLUTION Adrenergic Inhibitors COREG CARVEDILOL 12.5MG TABLET Adrenergic Inhibitors COREG CARVEDILOL 25MG TABLET Adrenergic Inhibitors COREG CARVEDILOL 3.125MG TABLET Adrenergic Inhibitors COREG CARVEDILOL 6.25MG TABLET Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 10MG CPMP 24HR Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 20MG CPMP 24HR P A Therapeutic Class Brand Name Status Generic Name Strength Form Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 30MG CPMP 24HR Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 40MG CPMP 24HR Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 10mg CPMP 24Hr Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 20mg CPMP 24Hr Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 40mg CPMP 24Hr Adrenergic Inhibitors COREG CR CARVEDILOL PHOSPHATE 80mg CPMP 24Hr Adrenergic Inhibitors TRANDATE LABETALOL HCL 100MG TABLET Adrenergic Inhibitors TRANDATE LABETALOL HCL 200MG TABLET Adrenergic Inhibitors TRANDATE LABETALOL HCL 300MG TABLET Agents to treat Multiple Sclerosis AVONEX INTERFERON BETA-1A 30MCG/.5ML KIT Agents to treat Multiple Sclerosis AVONEX ADMINISTRATION PAC INTERFERON BETA-1A/ALBUMI 30MCG KIT Agents to treat Multiple Sclerosis BETASERON INTERFERON BETA-1B 0.3MG VIAL Agents to treat Multiple Sclerosis COPAXONE GLATIRAMER ACETATE 20MG KIT Agents to treat Multiple Sclerosis REBIF INTERFERON BETA-1A/ALBUMI 22MCG/.5ML DISP SYRIN P A Therapeutic Class Brand Name Status Generic Name Strength Form Agents to treat Multiple Sclerosis REBIF INTERFERON BETA-1A/ALBUMI 44MCG/.5ML DISP SYRIN 8.8mcg/.5cc- Agents to treat Multiple Sclerosis REBIF TITRATION PACK INTERFERON BETA-1A/ALBUMI 22mcg/.5cc DISP SYRIN Alkylating Agents ALKERAN MELPHALAN 2MG TABLET Alkylating Agents ALKERAN MELPHALAN HCL 50MG VIAL Alkylating Agents CEENU LOMUSTINE 100MG CAPSULE Alkylating Agents CEENU LOMUSTINE 10-40-100 CAPSULE Alkylating Agents CEENU LOMUSTINE 10MG CAPSULE Alkylating Agents CEENU LOMUSTINE 40MG CAPSULE Alkylating Agents CYTOXAN CYCLOPHOSPHAMIDE 25MG TABLET Alkylating Agents CYTOXAN CYCLOPHOSPHAMIDE 50MG TABLET Alkylating Agents HEXALEN ALTRETAMINE 50MG CAPSULE Alkylating Agents HYDREA HYDROXYUREA 500MG CAPSULE Alkylating Agents LEUKERAN CHLORAMBUCIL 2MG TABLET Alkylating Agents MYLERAN BUSULFAN 2MG TABLET Alkylating Agents MYLOCEL HYDROXYUREA 1000MG TABLET Alkylating Agents TEMODAR TEMOZOLOMIDE 100MG CAPSULE Alkylating Agents TEMODAR TEMOZOLOMIDE 20MG CAPSULE Alkylating Agents TEMODAR TEMOZOLOMIDE 250MG CAPSULE Alkylating Agents TEMODAR TEMOZOLOMIDE 5MG CAPSULE Alkylating Agents TEMODAR TEMOZOLOMIDE 140mg CAPSULE Alkylating Agents TEMODAR TEMOZOLOMIDE 180mg CAPSULE Alkylating Agents URACIL MUSTARD URACIL MUSTARD 1MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form Alpha-2 Receptor Antagonist Antidepressants MIRTAZAPINE MIRTAZAPINE 7.5MG TABLET Alpha-2 Receptor Antagonist Antidepressants REMERON MIRTAZAPINE 15MG TAB RAPDIS Alpha-2 Receptor Antagonist Antidepressants REMERON MIRTAZAPINE 15MG TABLET Alpha-2 Receptor Antagonist Antidepressants REMERON MIRTAZAPINE 30MG TAB RAPDIS Alpha-2 Receptor Antagonist Antidepressants REMERON MIRTAZAPINE 30MG TABLET Alpha-2 Receptor Antagonist Antidepressants REMERON MIRTAZAPINE 45MG TAB RAPDIS Alpha-2 Receptor Antagonist Antidepressants REMERON MIRTAZAPINE 45MG TABLET Alpha-Adrenergic Blocking Agents CARDURA DOXAZOSIN MESYLATE 1MG TABLET Alpha-Adrenergic Blocking Agents CARDURA DOXAZOSIN MESYLATE 2MG TABLET Alpha-Adrenergic Blocking Agents CARDURA DOXAZOSIN MESYLATE 4MG TABLET Alpha-Adrenergic Blocking Agents CARDURA DOXAZOSIN MESYLATE 8MG TABLET Alpha-Adrenergic Blocking Agents DIBENZYLINE PHENOXYBENZAMINE HCL 10MG CAPSULE Alpha-Adrenergic Blocking Agents HYTRIN TERAZOSIN HCL 10MG CAPSULE Alpha-Adrenergic Blocking Agents HYTRIN TERAZOSIN HCL 1MG CAPSULE Alpha-Adrenergic Blocking Agents HYTRIN TERAZOSIN HCL 2MG CAPSULE Alpha-Adrenergic Blocking Agents HYTRIN TERAZOSIN HCL 5MG CAPSULE Alpha-Adrenergic Blocking Agents MINIPRESS PRAZOSIN HCL 1MG CAPSULE Alpha-Adrenergic Blocking Agents MINIPRESS PRAZOSIN HCL 2MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form Alpha-Adrenergic Blocking Agents MINIPRESS PRAZOSIN HCL 5MG CAPSULE ALTACE RAMIPRIL Hypotensives, ACE Blocking Agents 1.25MG TABLET ALTACE RAMIPRIL Hypotensives, ACE Blocking Agents 2.5MG TABLET ALTACE RAMIPRIL Hypotensives, ACE Blocking Agents 5MG TABLET ALTACE RAMIPRIL Hypotensives, ACE Blocking Agents 10MG TABLET Amebacides HUMATIN PAROMOMYCIN SULFATE 250MG CAPSULE Amebacides YODOXIN IODOQUINOL 210MG TABLET Amebacides YODOXIN IODOQUINOL 650MG TABLET Aminoglycosides NEO-FRADIN NEOMYCIN SULFATE 125MG/5ML SOLUTION Aminoglycosides NEOMYCIN SULFATE NEOMYCIN SULFATE 500MG TABLET Aminoglycosides TOBI TOBRAMYCIN/0.25 NORMAL SA 300MG/5ML AMPUL-NEB. Ammonia Inhibitors CEPHULAC LACTULOSE 10G/15ML SYRUP Analgesics, Antipyretics, Non-Salicylate ESGIC ACETAMINOPHEN/CAFFEINE/BU 325-40-50 CAPSULE Analgesics, Antipyretics, Non-Salicylate ESGIC ACETAMINOPHEN/CAFFEINE/BU 325-40-50 TABLET P A Therapeutic Class Brand Name Status Generic Name Strength Form Analgesics, Antipyretics, Non-Salicylate ESGIC PLUS ACETAMINOPHEN/CAFFEINE/BU 500-40-50 CAPSULE Analgesics, Antipyretics, Non-Salicylate ESGIC-PLUS ACETAMINOPHEN/CAFFEINE/BU 500-40-50 TABLET Analgesics, Antipyretics, Non-Salicylate REPAN-CF ACETAMINOPHEN/BUTALBITAL 650-50MG TABLET PA Analgesics, Narcotics ACTIQ Required FENTANYL CITRATE 1200MCG LOLLIPOP PA Analgesics,
Load more

Recommended publications
  • Postmenopausal Pharmacotherapy Newsletter
    POSTMENOPAUSAL PHARMACOTHERAPY September, 1999 As Canada's baby boomers age, more and more women will face the option of Hormone Replacement Therapy (HRT). The HIGHLIGHTS decision can be a difficult one given the conflicting pros and cons. M This RxFiles examines the role and use of HRT, as well as newer Long term HRT carries several major benefits but also risks SERMS and bisphosphonates in post-menopausal (PM) patients. which should be evaluated on an individual and ongoing basis MContinuous ERT is appropriate for women without a uterus HRT MWomen with a uterus should receive progestagen (at least 12 HRT is indicated for the treatment of PM symptoms such as days per month or continuous low-dose) as part of their HRT vasomotor disturbances and urogenital atrophy, and is considered MLow-dose ERT (CEE 0.3mg) + Ca++ appears to prevent PMO primary therapy for prevention and treatment of postmenopausal MBisphosphinates (e.g. alendronate, etidronate) and raloxifene are osteoporosis (PMO).1 Contraindications are reviewed in Table 2. alternatives to HRT in treating and preventing PMO Although HRT is contraindicated in women with active breast or M"Natural" HRT regimens can be compounded but data is lacking uterine cancer, note that a prior or positive family history of these does not necessarily preclude women from receiving HRT.1 Comparative Safety: Because of differences between products, some side effects may be alleviated by switching from one product Estrogen Replacement Therapy (ERT) 2 to another, particularly from equine to plant sources or from oral to Naturally secreted estrogens include: topical (see Table 3 - Side Effects & Their Management).
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Clinical Review, Adverse Events
    Clinical Review, Adverse Events Drug: Carbamazepine NDA: 16-608, Tegretol 20-712, Carbatrol 21-710, Equetro Adverse Event: Stevens-Johnson Syndrome Reviewer: Ronald Farkas, MD, PhD Medical Reviewer, DNP, ODE I 1. Executive Summary 1.1 Background Carbamazepine (CBZ) is an anticonvulsant with FDA-approved indications in epilepsy, bipolar disorder and neuropathic pain. CBZ is associated with Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), closely related serious cutaneous adverse drug reactions that can be permanently disabling or fatal. Other anticonvulsants, including phenytoin, phenobarbital, and lamotrigine are also associated with SJS/TEN, as are members of a variety of other drug classes, including nonsteriodal anti-inflammatory drugs and sulfa drugs. The incidence of CBZ-associated SJS/TEN has been considered “extremely rare,” as noted in current U.S. drug labeling. However, recent publications and postmarketing data suggest that CBZ- associated SJS/TEN occurs at a much higher rate in some Asian populations, about 2.5 cases per 1,000 new exposures, and that most of this increased risk is in individuals carrying a specific human leukocyte antigen (HLA) allele, HLA-B*1502. This HLA-B allele is present in about 5- to 20% of many, but not all, Asian populations, and is also present in about 2- to 4% of South Asians/Indians. The allele is also present at a lower frequency, < 1%, in several other ethnic groups around the world (although likely due to distant Asian ancestry). About 10% of U.S. Asians carry HLA-B*1502. HLA-B*1502 is generally not present in the U.S.
    [Show full text]
  • Design, Synthesis, and Evaluation of Antiepileptic Compounds Based on Β-Alanine and Isatin
    Design, Synthesis, and Evaluation of Antiepileptic Compounds Based on β-Alanine and Isatin by Robert Philip Colaguori A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Pharmaceutical Sciences University of Toronto © Copyright by Robert Philip Colaguori, 2016 ii Design, Synthesis, and Evaluation of Antiepileptic Compounds Based on β-Alanine and Isatin Robert Philip Colaguori Master of Science Department of Pharmaceutical Sciences University of Toronto 2016 Abstract Epilepsy is the fourth-most common neurological disorder in the world. Approximately 70% of cases can be controlled with therapeutics, however 30% remain pharmacoresistant. There is no cure for the disorder, and patients affected are subsequently medicated for life. Thus, there is a need to develop compounds that can treat not only the symptoms, but also delay/prevent progression. Previous work resulted in the discovery of NC-2505, a substituted β-alanine with activity against chemically induced seizures. Several N- and α-substituted derivatives of this compound were synthesized and evaluated in the kindling model and 4-AP model of epilepsy. In the kindling model, RC1-080 and RC1-102 were able to decrease the mean seizure score from 5 to 3 in aged mice. RC1-085 decreased the interevent interval by a factor of 2 in the 4-AP model. Future studies are focused on the synthesis of further compounds to gain insight on structure necessary for activity. iii Acknowledgments First and foremost, I would like to thank my supervisor Dr. Donald Weaver for allowing me to join the lab as a graduate student and perform the work ultimately resulting in this thesis.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Daniel Bovet
    D ANIEL B OVET The relationships between isosterism and competitive phenomena in the field of drug therapy of the autonomic nervous system and that of the neuromuscular transmission Nobel Lecture, December 11, 1957 Putting to good use the vast possibilities which organic synthesis offers, a number of workers have directed their efforts towards applying it to thera- peutics, and have sought to establish the bases of a science of pharmaceutical chemistry, or, more exactly perhaps, the bases of a science of chemical pharmacology worthy of this name. If such an ambitious programme has not yet been fully realized, we are at least justified in recognizing, in the work which has now been in progress for fifty years, the appearance of a few guiding principles whose value has not ceased to assert itself. This is particularly true, for example, in the case of ideas in isosterism and com- petition. The origin of many drugs must be looked for in substances of a biological nature, and in particular in the alkaloids. The elucidation of their structure has been a starting-off point for chemists to synthesize similar compounds. Cocaine, atropine, and morphia are particularly good examples in this respect, since substances which are made like them have shown, clinically, local anaesthetic, antispasmodic, and marked analgesic properties, respective- ly. In each of these cases the physiological properties of the new compound seem to be similar to the compound to which it is structurally related. This has been verified in many other fields, but it is nevertheless evident that in certain cases, molecules which are chemically closely related have very dif- ferent and even antagonistic properties.
    [Show full text]
  • Tegretol (Carbamazepine)
    Page 3 Tegretol® carbamazepine USP Chewable Tablets of 100 mg - red-speckled, pink Tablets of 200 mg – pink Suspension of 100 mg/5 mL Tegretol®-XR (carbamazepine extended-release tablets) 100 mg, 200 mg, 400 mg Rx only Prescribing Information WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT- RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH TEGRETOL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE WARNINGS AND PRECAUTIONS/LABORATORY TESTS). APLASTIC ANEMIA AND AGRANULOCYTOSIS APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF TEGRETOL. DATA FROM A POPULATION-BASED CASE CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.
    [Show full text]
  • Hormone Replacement Therapy and Osteoporosis
    This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting.
    [Show full text]
  • High-Throughput Brain Activity Mapping and Machine Learning As a Foundation for Systems Neuropharmacology
    High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology Lin, Xudong; Duan, Xin; Jacobs, Claire; Ullmann, Jeremy; Chan, Chung-Yuen; Chen, Siya; Cheng, Shuk-Han; Zhao, Wen-Ning; Poduri, Annapurna; Wang, Xin; Haggarty, Stephen J.; Shi, Peng Published in: Nature Communications Published: 03/12/2018 Document Version: Final Published version, also known as Publisher’s PDF, Publisher’s Final version or Version of Record License: CC BY Publication record in CityU Scholars: Go to record Published version (DOI): 10.1038/s41467-018-07289-5 Publication details: Lin, X., Duan, X., Jacobs, C., Ullmann, J., Chan, C-Y., Chen, S., Cheng, S-H., Zhao, W-N., Poduri, A., Wang, X., Haggarty, S. J., & Shi, P. (2018). High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology. Nature Communications, 9, [5142]. https://doi.org/10.1038/s41467-018-07289- 5 Citing this paper Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details. General rights Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.
    [Show full text]